Abstract
LINC00511 is a newly identified lncRNA that is up-regulated in many types of human cancers and may serve as an oncogenic lncRNA. However, there was no report about the role of LINC00511 in cervical cancer. Therefore, we investigated the clinical value of LINC00511 in cervical cancer patients via analyzing the correlation between LINC00511 expression and clinicopathological features. Moreover, we performed loss-of-function study to estimate the effect of LINC00511 on cervical cancer cell proliferation, migration, and invasion. In our study, we found LINC00511 expression levels were increased in cervical cancer tissues and cell lines compared with adjacent normal tissues and normal cervical epithelial cell line, respectively. High LINC00511 expression was correlated with advanced clinical stage, large tumor size, histological type of adenocarcinoma, and present lymph node metastasis, distant metastasis, and poor overall survival in cervical cancer patients. The in vitro studies indicated that knockdown of LINC00511 inhibited cervical cancer cell proliferation, migration, and invasion. In conclusion, LINC00511 acts as oncogenic lncRNA in cervical cancer, and may be a novel biomarker and potential therapeutic target for cervical cancer patients.
Highlights
Cervical cancer is the fourth most common female malignancy in the world accounting for approximately 6.6% of all newly diagnosed female cancers [1]
Cabanski et al conducted a pan-cancer analysis of long noncoding RNA (lncRNA) comparing cancer tissue samples and matched normal tissue samples expression levels using RNA-Seq data in eight types of human cancers, and found levels of LINC00511 expression were significantly elevated in invasive breast cancer, lung adenocarcinoma, lung squamous cell carcinoma, colorectal cancer compared with corresponding normal tissues [13]
High expression of LINC00511 was further confirmed in lung adenocarcinoma [14], lung squamous cell carcinoma [14], breast cancer [21], pancreatic cancer [22], bladder cancer [23], osteosarcoma [24], and tongue squamous cell carcinoma [25]
Summary
Cervical cancer is the fourth most common female malignancy in the world accounting for approximately 6.6% of all newly diagnosed female cancers [1]. Cervical cancer ranks the fourth leading cause of cancer-related death in women worldwide accounting for 311365 deaths in 2018 [1]. Cervical cancer often derives from abnormal cell growth with human papillomavirus (HPV) infection on the cervix [2]. The generalization of disease screening and introduction of HPV vaccines jointly result in a decreasing incidence trend for cervical cancer in most countries [3,4]. The improvement of cervical cancer treatment strategy is limited [5,6]. Chemotherapy, and radiotherapy are still the major therapies for cervical cancer patients [7,8,9]. It is necessary to investigate the molecular mechanisms of cervical cancer development for gaining novel therapeutic targets
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
